2U
2U3.STU Alcon Inc
- Market cap
- EUR 44.0B
- P/E
- 108.0x
- P/B
- 1.47x
- ROE
- 1.8%
- Dividend yield
- 0.44%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 2U3.STU undervalued?
Graham number2U3.STU trades 165.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alcon Inc fundamental analysis
No fundamental analysis for Alcon Inc yet.
Alcon Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alcon Inc
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract produ…
Full company profileAlcon Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alcon Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.60B | 6.79B | 7.28B | 7.51B | 6.83B | 8.29B | 8.72B | 9.46B | 9.91B | 10.4B | 11.1B |
| Gross Profit | 3.11B | 3.20B | 3.19B | 3.66B | 2.94B | 4.65B | 4.75B | 5.25B | 5.51B | 5.75B | 6.40B |
| Operating Income | 10.0M | -77.0M | -248M | -187M | -427M | 580M | 672M | 1.04B | 1.41B | 1.36B | 606M |
| EBITDA | - | 1.21B | 1.35B | 1.21B | 1.12B | 1.76B | 1.72B | 2.24B | 2.68B | 2.70B | 2.83B |
| Net Income | -170M | 256M | -315M | -656M | -531M | 376M | 335M | 974M | 1.02B | 980M | 378M |
| EPS | - | 0.52 | -0.65 | -1.34 | -1.09 | 0.77 | 0.68 | 1.97 | 2.06 | 2.01 | 0.78 |
| Balance Sheet | |||||||||||
| Total Assets | - | 27.4B | 27.3B | 27.7B | 27.6B | 28.0B | 29.2B | 29.6B | 30.3B | 31.6B | 31.1B |
| Total Liabilities | - | 4.36B | 7.79B | 8.35B | 8.78B | 8.74B | 9.53B | 8.99B | 8.79B | 9.52B | 9.50B |
| Shareholders' Equity | - | 23.0B | 19.5B | 19.3B | 18.8B | 19.3B | 19.7B | 20.6B | 21.6B | 22.0B | 21.6B |
| Cash & Short-term Investments | - | 172M | 500M | 822M | 1.56B | 1.58B | 980M | 1.09B | 1.68B | 1.53B | 1.36B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.25B | 1.22B | 1.14B | 920M | 823M | 1.35B | 1.22B | 1.39B | 2.08B | 2.27B | 1.86B |
| Capital Expenditure | 506M | 415M | 524M | 553M | 479M | 700M | 636M | 851M | 670M | 663M | 662M |
| Free Cash Flow | - | 722M | 428M | 244M | 256M | 165M | 472M | 537M | 1.41B | 1.61B | 1.19B |
| Ratios | |||||||||||
| ROE | - | 1.1% | -1.6% | -3.4% | -2.8% | 2.0% | 1.7% | 4.7% | 4.7% | 4.4% | 1.8% |
| ROA | - | 0.9% | -1.2% | -2.4% | -1.9% | 1.3% | 1.1% | 3.3% | 3.4% | 3.1% | 1.2% |
| Net Profit Margin | -2.6% | 3.8% | -4.3% | -8.7% | -7.8% | 4.5% | 3.8% | 10.3% | 10.3% | 9.4% | 3.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Alcon Inc dividends
- Dividend yield
- 0.44%
- Forward dividend
- -
- Payout ratio
- 16.9%
- Ex-dividend date
- May 4, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 166M | 0.34 | 16.9% |
| 2024 | USD 130M | 0.26 | 12.8% |
| 2023 | USD 116M | 0.24 | 11.9% |
| 2022 | EUR 100M | 0.20 | 29.9% |
| 2021 | EUR 54.0M | 0.11 | 14.4% |
| 2020 | EUR 54.0M | 0.11 | - |
| 2019 | EUR 54.0M | 0.11 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Alcon Inc
- Insiders 0.06%
- Institutions 61.46%
- Public & others 38.49%
- Shares outstanding 490M
- Free float 490M
Alcon Inc company profile
- Company name
- Alcon Inc
- Ticker
- 2U3.STU
- ISIN
- CH0432492467
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 23,000
- Fiscal year end
- December
- Address
- Chemin de Blandonnet 8, Geneva, Switzerland
- Phone
- 41 58 911 2110
- Website
- alcon.com
About Alcon Inc
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; and EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, including devices and over-the-counter products for dry eye, over-the-counter products for contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. Alcon, Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Alcon Inc management
10- Mr. F. Michael BallExec. Chairman · born 1955
- Mr. David J. EndicottCEO & Director · born 1965
- Mr. Arthur B. Cummings M.D.Exec. Director · born 1962
- Mr. Timothy C. StonesiferChief Financial Officer · born 1967
- Margaret BuckleyChief Accounting Officer
- Ms. Sue-Jean LinSr. VP & Chief Information and Transformation Officer
- Ms. Karen KingSr. VP and Head of Global Investor Relations & Communications
- Mr. Royce R. BedwardSr. VP, Gen. Counsel & Corp. Sec. · born 1966
- Mr. Laurent AttiasHead of Corp. Devel., Strategy, BD&L and M&A · born 1968
- Ms. Kimberly MartinSr. VP & Chief HR Officer · born 1975